Clinical Study in Children, 6 Months to 3 Years of Age, to Assess the Immunogenicity and Safety of Two Dose Levels of Thimerosal-Free Fluviral Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip as the Control.
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2016
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 23 Sep 2009 Actual patient number (403) added as reported by ClinicalTrials.gov.
- 23 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2009 Planned end date changed from 1 Jul 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.